Soleno Therapeutics (SLNO) Stock Price, News & Analysis

Company Overview

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key Stats

• Today's Range: $72.78 to $74.27
• 50-Day Range: $43.68 to $74.23
• 52-Week Range: $36.93 to $74.50
• Volume: 776,359 shs
• Average Volume: 737,909 shs
• Market Capitalization: $3.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $104.67
• Consensus Rating: Buy

Soleno Therapeutics Stock Analysis - MarketRank™

Soleno Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 69th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Soleno Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.72) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soleno Therapeutics is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soleno Therapeutics is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soleno Therapeutics has a P/B Ratio of 14.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.65% of the float of Soleno Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Soleno Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Soleno Therapeutics has recently increased by 7.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soleno Therapeutics does not currently pay a dividend.

Dividend Growth

Soleno Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.55

Percentage of Shares Shorted

12.65% of the float of Soleno Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Soleno Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Soleno Therapeutics has recently increased by 7.51%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.36

News Sentiment

Soleno Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Soleno Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

12 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,058,781.00 in company stock.

Percentage Held by Insiders

12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLNO Stock Analysis - Frequently Asked Questions

How have SLNO shares performed this year?

Soleno Therapeutics' stock was trading at $44.95 at the beginning of the year. Since then, SLNO stock has increased by 63.0% and is now trading at $73.26.
View the best growth stocks for 2025 here.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its quarterly earnings data on Wednesday, March, 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.41.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics shares reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Soleno Therapeutics' major shareholders?

Top institutional shareholders of Soleno Therapeutics include Assenagon Asset Management S.A. (0.95%), Allspring Global Investments Holdings LLC (0.15%), Harbor Capital Advisors Inc. (0.10%) and Rhumbline Advisers (0.08%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen, Michael F Huang, Patricia C Hirano and Matthew Pauls.
View institutional ownership trends.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/05/2025
• Today: 4/27/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SLNO
• CIK: 1484565
• Web: www.soleno.life
• Phone: (650) 213-8444
• Fax: 650-213-8383
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $104.67
• High Stock Price Target: $145.00
• Low Stock Price Target: $73.00
• Potential Upside/Downside: +42.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-38,990,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.99%
• Return on Assets: -55.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.26
• Quick Ratio: 17.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.16 per share
• Price / Book: 14.20

Miscellaneous

• Outstanding Shares: 45,857,000
• Free Float: 37,814,000
• Market Cap: $3.36 billion
• Optionable: Optionable
• Beta: -2.29